Testing sevabertinib for advanced HER2-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have advanced non-small cell lung cancer that has spread or cannot be treated with surgery or radiation.
- Your cancer has a specific change in the HER2 gene, called a HER2 mutation, found through a tumor biopsy.
- You have not had any previous treatment for advanced or metastatic lung cancer.
- You are able to receive standard platinum-based chemotherapy along with pembrolizumab (immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This expanded access program provides sevabertinib, an investigational pill, to people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called a HER2 mutation and has stopped responding to previous treatments. The goal is to offer potential treatment when no other options are available.
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
This trial tests a new drug called vebreltinib combined with standard chemotherapy for advanced non-small cell lung cancer (a common type of lung cancer) in patients whose tumors show high levels of a protein called MET. The goal is to see if this combination can slow cancer growth better than chemotherapy alone.
This trial tests a new drug called zongertinib combined with chemotherapy, with or without pembrolizumab (an immunotherapy), for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see how safe and well-tolerated the combination is.
This trial tests a combination of two experimental drugs (vebreltinib plus PLB1004) against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR mutation positive, MET positive) that has gotten worse after prior EGFR-targeted therapy.
Hear when a new Advanced Non-small Cell Lung Cancer, HER2 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.